Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Denifanstat · TVB-2640, ASC-40

Small molecule · Inhibitor of fatty acid synthase (FASN) · developed by Sagimet Biosciences

Phase 3 Most advanced trial
SGMT Developer
5 Registered trials

What is Denifanstat?

Denifanstat is an orally bioavailable inhibitor of fatty acid synthase (FASN), an enzyme that drives de novo synthesis of palmitic acid. By blocking FASN it reduces palmitate needed for tumor cell growth and survival. It is studied in KRAS-mutated tumors, acne vulgaris, and steatohepatitis (MASH/NASH), among other conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TVB-2640, ASC-40, [14C]-TVB-2640
Drug type
Small molecule
Targets
fatty acid synthase (FASN)
Mechanism
Inhibitor of fatty acid synthase (FASN)
Pathways
de novo palmitate synthesis, lipid signaling, tumor cell survival
Therapy area
Dermatology, Gastroenterology
Developer
Sagimet Biosciences Inc. (SGMT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
4GF95B2LZA

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07863193 Phase 3 Acne Vulgaris Recruiting SGMT
NCT03808558 Phase 2 KRAS Gene Mutation Active not recruiting SGMT
NCT03938246 Phase 2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease /… Completed SGMT
NCT05835180 Phase 1 Non-alcoholic Steatohepatitis Completed SGMT
NCT05657834 Phase 1 Healthy Volunteers Completed SGMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne VulgarisKRAS Gene MutationCirrhosisHealthy VolunteersHepatic ImpairmentNon-alcoholic Steatohepatitis

More from Sagimet Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SGMT page.

Follow SGMT, the company behind Denifanstat

See SGMT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SGMT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.